Barring supply issues, 100M doses in 100 days is an extremely low bar to meet and ending up anywhere around that would have to be considered a big failure. Deliveries are expected to come in at more than double that.
Right now, the US doesn't have a problem due to lack of doses ordered or distribution issues; they're just hitting the limits of the manufacturing capabilities of the companies. Pfizer and Moderna are only delivering about 8.5M doses a week (1.2M a day) right now and the US is administering about that many per day at this point. That will have to increase (by almost double) if they're going to meet their 200M doses by the end of March, but as long as administered doses are matching the deliveries, the bottleneck is production, like it is everywhere else in the world.
|